Aligos Therapeutics financials
$5.62+1.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $2.2M | $3.9M | $15.5M | $13.9M | $4.4M | — |
| Gross profit | $2.2M | $3.9M | $15.5M | $13.9M | $4.4M | — |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$88.0M | -$89.2M | -$84.7M | -$95.9M | -$128.2M | -$108.4M |
| Net income | -$24.2M | -$131.2M | -$87.7M | -$96.0M | -$128.3M | -$108.5M |
| Net margin | −1106.7% | −3326.0% | −564.6% | −690.6% | −2944.1% | — |
| Diluted EPS | $-2.45 | $-20.94 | $-34.20 | $-56.25 | $-80.50 | $-271.75 |
| EBITDA | -$87.1M | -$88.1M | -$83.2M | -$92.3M | -$125.2M | -$105.6M |
| Operating cash flow | -$82.5M | -$80.7M | -$79.0M | -$79.4M | -$115.7M | -$74.3M |
| Free cash flow | -$82.9M | -$80.9M | -$79.0M | -$80.3M | -$116.6M | -$76.3M |
| Diluted shares | 9.9M | 6.3M | 2.6M | 1.7M | 1.6M | 0.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.3M | $37.0M | $135.7M | $81.3M | $186.8M | $220.4M |
| Short-term investments | $59.5M | $19.9M | $0.00 | $44.5M | $3.9M | $23.1M |
| Total debt | $145.0K | $204.0K | $287.0K | $338.0K | $532.0K | $573.0K |
| Total assets | $88.5M | $70.1M | $151.5M | $146.7M | $235.4M | $265.3M |
| Total liabilities | $35.0M | $99.1M | $59.4M | $42.8M | $50.6M | $45.3M |
| Shareholders' equity | $53.5M | -$29.0M | $92.1M | $103.9M | $184.7M | $220.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology